September 2017 Issue Table Of Contents

From The Editor

• Life, Liberty, And The Pursuit Of Healthiness

Feature Articles

• Behind The Scenes Of Allergan’s Social Contract
• P3s: How To Get The Good …Without The Bad
• Cytokinetics: Keeping Its Sights On Independence

Capitol Perspectives

• Part D Is Due For A Tune-Up

Companies To Watch

• Arena Pharmaceuticals

CEO Corner

• Successfully Transforming An Organization: An Active Approach

Inside The Industry

• Whistleblower Best Practices
• What To Know If (Or When) The DOJ Evaluates Your Compliance Program
• Lessons In Collaborating With Big Pharma
• Reaching A Turning Point With An Unusual Cancer Therapeutic
• Little Rhode Island Has Big Ambitions To Be A Regional Life Sciences Hub
• Preparing For A Blockchain-Enabled World

Leadership Lessons

• Disrupt Yourself Before Somebody Or Something Else Does

Industry Leader

• Research Reveals Critical Need To Eliminate Clinical Silos

Ask The Board

• What Were Some Of The Most Valuable Lessons Learned During Shire’s Acquisition Of NPS Pharmaceuticals?
• Knowing What You Know Now, What If Anything, Would You Do Differently In Approaching Your Career?
• What Are Some Of The Most Interesting Insights Gained From Serving On A Corporate Board That Have Made You A Better Leader?
• Could A Value-Based Drug Pricing System Lead To Higher Drug Prices?